Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3567

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3567
---
 be limited to the appreciation of their stock.

Our
principal stockholders and management own a significant percentage of our common stock and are able to exert significant control
over matters subject to stockholder approval.

Our
executive officers, directors and their affiliates and our principal stockholders beneficially hold, in the aggregate, approximately
75% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring
stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of
our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

124

Our
issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, employee stock
purchase plan or otherwise will dilute all other stockholders.

We
expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity
awards to employees, directors, and consultants under our stock incentive plans and employee stock purchase plan. We may also raise capital
through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies,
products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional
capital stock, including as a result of the exercise of any warrants to purchase shares of common stock, may cause stockholders to experience
significant dilution of their ownership interests and the per share value of our common stock to decline.

We
will incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance
with its public company responsibilities and corporate governance practices.

As
a public company, we will incur significant legal, accounting and other expenses that Legacy Ocean did not incur as a private company,
and these expenses may increase even more after we are no longer an emerging growth company, as defined in Section 2(a) of the Securities
Act.

We
are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, which require, among other things, that
we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley
Act